Scarica l'app Stockscreener
320.95
0.73%
-2.37
Dopo l'orario di chiusura:
320.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$323.32
Aprire:
$326.34
Volume 24 ore:
1.16M
Relative Volume:
0.83
Capitalizzazione di mercato:
$61.25B
Reddito:
$328.68B
Utile/perdita netta:
$2.55B
Rapporto P/E:
24.62
EPS:
13.0349
Flusso di cassa netto:
$1.56B
1 W Prestazione:
-4.82%
1M Prestazione:
-1.25%
6M Prestazione:
-8.87%
1 anno Prestazione:
+8.31%
Intervallo 1D:
$320.91
$327.90
Intervallo di 1 settimana:
$320.91
$336.01
Portata 52W:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Nome
Cencora Inc
Settore
Industria
Telefono
610-727-7000
Indirizzo
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
320.95 | 61.70B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
880.86 | 103.96B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
236.02 | 55.82B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
87.30 | 9.80B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
0.7302 | 685.45M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Ripresa | Mizuho | Outperform |
| 2024-09-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-03 | Iniziato | Barclays | Overweight |
| 2023-12-14 | Iniziato | Wells Fargo | Equal Weight |
| 2023-03-31 | Iniziato | Citigroup | Buy |
| 2023-01-31 | Ripresa | Evercore ISI | Outperform |
| 2022-10-11 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Ripresa | Evercore ISI | In-line |
| 2021-02-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-01-06 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Iniziato | Mizuho | Neutral |
| 2020-08-06 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Iniziato | Barclays | Underweight |
| 2020-06-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Ripresa | Credit Suisse | Outperform |
| 2020-04-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-11 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Iniziato | Deutsche Bank | Hold |
| 2019-07-10 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Iniziato | Guggenheim | Buy |
| 2019-04-10 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Iniziato | UBS | Buy |
| 2018-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2018-10-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Iniziato | Berenberg | Buy |
| 2018-07-17 | Ripresa | Stifel | Hold |
| 2018-04-09 | Iniziato | MoffettNathanson | Buy |
| 2018-03-12 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Iniziato | JP Morgan | Neutral |
| 2017-09-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Cencora Inc Borsa (COR) Ultime notizie
Cencora stock heads into the open after a 0.1% dip - ad-hoc-news.de
Cencora Inc. stock dips after RBC reiterates cautious price target - ad-hoc-news.de
Is Cencora Stock Underperforming the Dow? - Yahoo Finance
Cencora stock heads into the open after a modest decline - ad-hoc-news.de
Cencora stock holds firm after RBC keeps $330 target - ad-hoc-news.de
Cencora Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cencora stock price target maintained at $330 by RBC Capital - Investing.com Canada
Cencora, Inc. (COR) Stock Analysis: Robust Growth in Medical Distribution with an 11.59% Upside Potential - DirectorsTalk Interviews
Cencora Inc. stock gains on solid fiscal 2026 momentum - ad-hoc-news.de
Why Cencora (COR) Is Getting Attention Today - simplywall.st
Cencora’s New Cell and Gene Services Might Change The Case For Investing In Cencora (COR) - simplywall.st
Cencora Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Former Cencora (NYSE: COR) leader lines up another stock sale - Stock Titan
Cencora Inc. stock gains on new cell and gene therapy service and strong guidance - ad-hoc-news.de
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue? - Eastern Progress
Cencora Launches Cell and Gene Therapy Enablement for Health Systems - Eastern Progress
Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings? - Yahoo Finance
Cencora (COR) Unveils Cell And Gene Therapy Enablement Service - simplywall.st
What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders - Yahoo Finance
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen - Yahoo Finance
Cencora Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs - biobuzz.io
Artisan Sold Cencora (COR) as Earnings Momentum Slowed - Yahoo Finance
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora (NYSE: COR) executive sells 985 shares in preset plan - Stock Titan
Cencora Launches Cell and Gene Therapy Enablement Service Through Accelerate Pharmacy Solutions - marketscreener.com
Cencora Inc. stock reflects insider sale plans and steady growth outlook - ad-hoc-news.de
Former Cencora (NYSE: COR) executive lines up stock sale after restricted shares vest - Stock Titan
Cencora, Inc. (COR) Stock Analysis: A Healthcare Powerhouse with 14.68% Potential Upside - DirectorsTalk Interviews
Cencora (COR) Q2 2026 Earnings Call Transcript - Fortune
Cencora Executive VP & Chief Legal Officer Elizabeth Campbell Sells 37% Of Holding - simplywall.st
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? - Eastern Progress
Cencora (COR) Earnings History & Trends - 24/7 Wall St.
Elizabeth S Campbell Takes Money Off The Table, Sells $3.66M In Cencora Stock - Benzinga
Is Cencora (COR) Still Undervalued Following Its Board Resignation News? - Sahm
Cencora, Inc. (COR) Stock Analysis: A Healthcare Giant With A 16% Upside Potential - DirectorsTalk Interviews
Paralel Advisors LLC Purchases New Position in Cencora, Inc. $COR - MarketBeat
Silvant Capital Management LLC Invests $11.93 Million in Cencora, Inc. $COR - MarketBeat
$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Sahm
Fairtree Asset Management Pty Ltd Makes New $1.77 Million Investment in Cencora, Inc. $COR - MarketBeat
B. Metzler seel. Sohn & Co. AG Invests $9.62 Million in Cencora, Inc. $COR - MarketBeat
Algebris UK Ltd. Invests $969,000 in Cencora, Inc. $COR - MarketBeat
Cencora (NYSE:COR) Healthcare Growth Story Gains Fresh Momentum - Kalkine Media
Quartz Partners LLC Buys Shares of 15,650 Cencora, Inc. $COR - MarketBeat
United Bank Purchases New Stake in Cencora, Inc. $COR - MarketBeat
Shepherd Financial Partners LLC Takes Position in Cencora, Inc. $COR - MarketBeat
Meeder Advisory Services Inc. Purchases New Stake in Cencora, Inc. $COR - MarketBeat
Cencora (COR) Quarter in Focus: Profit Per Share Surpasses Its Benchmark for the Current Session; Latest Reaction: The Stock Ends Up 0.31% at the CloseGAAP Earnings Report - Vinanet
Great Lakes Advisors LLC Makes New Investment in Cencora, Inc. $COR - MarketBeat
Foster & Motley Inc. Takes $1.50 Million Position in Cencora, Inc. $COR - MarketBeat
Cencora Inc Azioni (COR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):